New Clinical Trial Explores Addition of Anti-Cancer Drug BAY 1895344 to Standard Chemotherapy
The phase 1a/1b clinical trial is being conducted in patients who have advanced small cell lung cancer, poorly differentiated neuroendocrine cancer, or pancreatic cancer. Satya Das, MD, MSCI, at Vanderbilt University Medical Center serves as principal investigator of the study, which is sponsored by the National Cancer Institute.
Firsty Family’s successful Moonlight Walk surpasses fundraising goal
The California family resumed an in-person event to raise money for NETRF in honor of wife and mother Julie Firsty.
Clinical Trial Focuses on Use of Lutetium 177 in Lung NETs
Promising clinical trial using Lutetium 177 in LungNETS.
Research Spotlight: Rodney Hicks, MD
Peptide receptor radionuclide therapy, or PRRT, has been available as a treatment option for some forms of neuroendocrine tumors – particularly for those NETs expressing the somatostatin receptor-2 (SSTR2) protein.
New Clinical Trial Focuses on Lutathera® in Adolescents with NETs
A phase II clinical trial has launched to study Lutathera® in adolescents with gastroenterpancreatic neuroendocrine tumors (GEP-NET), pheochromocyomas and paragangliomas (PPGLs).
NETRF Announces Changes to its Board of Scientific Advisors
The Neuroendocrine Tumor Research Foundation (NETRF) recently announced changes to the Board of Scientific Advisors (BOSA), extending its sincerest appreciation for the participation of Dung Thi Le, MD, and welcoming Jennifer Eads, MD
Biking for Debbie 2021
As another summer came to a close, the riders of Biking for Debbie were on the road again!
Celebrating Nathan Montoya’s Life and Spirit
One hundred friends and relatives gathered to celebrate Nathan Montoya’s life on July 24, 2021, which would have been his 43rd birthday.
Research Spotlight: Po Hien Ear, PhD
Dr. Po Hien Ear’s research involves growing NET spheroid clusters in large enough numbers to be used to screen the potential anti-tumor properties of hundreds of therapeutic compounds.
Clinical Trial of Belzutifan in Pancreatic NETs and Pheo/Para
A phase II clinical trial has opened to investigate the safety and effectiveness of the drug belzutifan for pancreatic neuroendocrine tumors (pNETs) and pheochromocytoma/paraganglioma (PPGL).